CO6721059A2 - Composiciones farmacéuticas de tenecteplasa - Google Patents

Composiciones farmacéuticas de tenecteplasa

Info

Publication number
CO6721059A2
CO6721059A2 CO13159374A CO13159374A CO6721059A2 CO 6721059 A2 CO6721059 A2 CO 6721059A2 CO 13159374 A CO13159374 A CO 13159374A CO 13159374 A CO13159374 A CO 13159374A CO 6721059 A2 CO6721059 A2 CO 6721059A2
Authority
CO
Colombia
Prior art keywords
tenecteplase
pharmaceutical compositions
compositions
tnk
treatment
Prior art date
Application number
CO13159374A
Other languages
English (en)
Inventor
Maheshwari Kumar Mishra
Pritiranjan Bhandari
Sanjay Singh
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6721059(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of CO6721059A2 publication Critical patent/CO6721059A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Abstract

La invención se refiere a composiciones farmacéuticas de tenecteplasa que son seguras y efectivas en el tratamiento del accidente cerebrovascular isquémico agudo comparadas con composiciones conocidas. Las composiciones de la invención se inventaron basándose en una serie de ensayos de prueba con diferentes cantidades de TNK y aislando las cantidades específicas que fueron óptimas en términos de los efectos deseados de TNK en el tratamiento de accidente cerebrovascular isquémico agudo, clínicos.
CO13159374A 2010-12-23 2013-07-05 Composiciones farmacéuticas de tenecteplasa CO6721059A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3516MU2010 2010-12-23

Publications (1)

Publication Number Publication Date
CO6721059A2 true CO6721059A2 (es) 2013-07-31

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13159374A CO6721059A2 (es) 2010-12-23 2013-07-05 Composiciones farmacéuticas de tenecteplasa

Country Status (17)

Country Link
US (2) US20130323227A1 (es)
EP (1) EP2654770B1 (es)
JP (1) JP6375112B2 (es)
CN (1) CN103391785A (es)
AU (1) AU2011346515B2 (es)
BR (1) BR112013015914B1 (es)
CO (1) CO6721059A2 (es)
DK (1) DK2654770T3 (es)
EA (1) EA026017B1 (es)
ES (1) ES2687850T3 (es)
LT (1) LT2654770T (es)
MX (1) MX356199B (es)
MY (1) MY171723A (es)
NZ (1) NZ611706A (es)
PL (1) PL2654770T3 (es)
PT (1) PT2654770T (es)
WO (1) WO2012085933A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017004470A (es) * 2014-10-21 2017-11-20 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa).
WO2018210860A1 (en) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
WO2019229764A1 (en) * 2018-06-01 2019-12-05 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
SG10201804944XA (en) * 2006-08-29 2018-07-30 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
US8916148B2 (en) * 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Also Published As

Publication number Publication date
BR112013015914B1 (pt) 2021-06-08
PL2654770T3 (pl) 2018-12-31
DK2654770T3 (en) 2018-10-29
EP2654770A4 (en) 2014-05-21
JP2014502608A (ja) 2014-02-03
EP2654770A1 (en) 2013-10-30
NZ611706A (en) 2015-04-24
MX356199B (es) 2018-05-18
US20130323227A1 (en) 2013-12-05
JP6375112B2 (ja) 2018-08-15
AU2011346515A1 (en) 2013-07-04
US9943575B2 (en) 2018-04-17
MY171723A (en) 2019-10-24
EP2654770B1 (en) 2018-07-11
EA201300746A1 (ru) 2013-11-29
US20160310580A1 (en) 2016-10-27
AU2011346515B2 (en) 2017-01-19
ES2687850T3 (es) 2018-10-29
CN103391785A (zh) 2013-11-13
PT2654770T (pt) 2018-10-19
LT2654770T (lt) 2018-09-10
BR112013015914A2 (pt) 2016-10-11
EA026017B1 (ru) 2017-02-28
WO2012085933A1 (en) 2012-06-28
MX2013007381A (es) 2013-08-29

Similar Documents

Publication Publication Date Title
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
PE20181155A1 (es) Composiciones que comprenden cepas bacterianas
ECSP15048555A (es) Heterociclos bicíclicos como inhibidores de fgfr
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
UY35210A (es) Inhibidores de autotaxina
AR089155A1 (es) Unidad de procesamiento de isomerizacion y transalquilacion de xileno combinada
AR093756A1 (es) Composiciones que comprenden polimeros cationicos hidrofobamente modificados
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
UY36075A (es) Derivados de tubulisina
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112015021880A2 (pt) rearranjo de vírus influenza b
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
UY37917A (es) Nuevos enantiómeros de una serie de compuestos antivirales
CO2017007899A2 (es) Composición biodegradable resistente a la humedad
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CO6721059A2 (es) Composiciones farmacéuticas de tenecteplasa
BR112015009179A2 (pt) composição à base de plantas